Alliança Saúde e Participações S.A.

BOVESPA:AALR3 Stock Report

Market Cap: R$1.2b

Alliança Saúde e Participações Past Earnings Performance

Past criteria checks 0/6

Alliança Saúde e Participações's earnings have been declining at an average annual rate of -47.4%, while the Healthcare industry saw earnings growing at 21.6% annually. Revenues have been growing at an average rate of 3.8% per year.

Key information

-47.4%

Earnings growth rate

-47.4%

EPS growth rate

Healthcare Industry Growth11.6%
Revenue growth rate3.8%
Return on equity-13.1%
Net Margin-13.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Risks Still Elevated At These Prices As Alliança Saúde e Participações S.A. (BVMF:AALR3) Shares Dive 26%

Dec 05
Risks Still Elevated At These Prices As Alliança Saúde e Participações S.A. (BVMF:AALR3) Shares Dive 26%

Alliança Saúde e Participações S.A. (BVMF:AALR3) Stock Rockets 36% As Investors Are Less Pessimistic Than Expected

Aug 25
Alliança Saúde e Participações S.A. (BVMF:AALR3) Stock Rockets 36% As Investors Are Less Pessimistic Than Expected

Optimistic Investors Push Alliança Saúde e Participações S.A. (BVMF:AALR3) Shares Up 60% But Growth Is Lacking

Jul 11
Optimistic Investors Push Alliança Saúde e Participações S.A. (BVMF:AALR3) Shares Up 60% But Growth Is Lacking

What Alliança Saúde e Participações S.A.'s (BVMF:AALR3) 26% Share Price Gain Is Not Telling You

Apr 17
What Alliança Saúde e Participações S.A.'s (BVMF:AALR3) 26% Share Price Gain Is Not Telling You

Centro de Imagem Diagnósticos (BVMF:AALR3) Will Be Hoping To Turn Its Returns On Capital Around

Aug 17
Centro de Imagem Diagnósticos (BVMF:AALR3) Will Be Hoping To Turn Its Returns On Capital Around

Why Centro de Imagem Diagnósticos S.A. (BVMF:AALR3) Could Be Worth Watching

Jul 08
Why Centro de Imagem Diagnósticos S.A. (BVMF:AALR3) Could Be Worth Watching

Is Centro de Imagem Diagnósticos (BVMF:AALR3) Using Too Much Debt?

May 28
Is Centro de Imagem Diagnósticos (BVMF:AALR3) Using Too Much Debt?

What Is Centro de Imagem Diagnósticos S.A.'s (BVMF:AALR3) Share Price Doing?

Apr 05
What Is Centro de Imagem Diagnósticos S.A.'s (BVMF:AALR3) Share Price Doing?

Reflecting on Centro de Imagem Diagnósticos' (BVMF:AALR3) Share Price Returns Over The Last Three Years

Mar 10
Reflecting on Centro de Imagem Diagnósticos' (BVMF:AALR3) Share Price Returns Over The Last Three Years

Should You Buy Centro de Imagem Diagnósticos S.A. (BVMF:AALR3) For Its Dividend?

Feb 17
Should You Buy Centro de Imagem Diagnósticos S.A. (BVMF:AALR3) For Its Dividend?

What Percentage Of Centro de Imagem Diagnósticos S.A. (BVMF:AALR3) Shares Do Insiders Own?

Jan 27
What Percentage Of Centro de Imagem Diagnósticos S.A. (BVMF:AALR3) Shares Do Insiders Own?

Would Centro de Imagem Diagnósticos (BVMF:AALR3) Be Better Off With Less Debt?

Jan 06
Would Centro de Imagem Diagnósticos (BVMF:AALR3) Be Better Off With Less Debt?

What Does Centro de Imagem Diagnósticos S.A.'s (BVMF:AALR3) Share Price Indicate?

Dec 11
What Does Centro de Imagem Diagnósticos S.A.'s (BVMF:AALR3) Share Price Indicate?

Centro de Imagem Diagnósticos S.A. (BVMF:AALR3) Is Yielding 0.8% - But Is It A Buy?

Aug 07
Centro de Imagem Diagnósticos S.A. (BVMF:AALR3) Is Yielding 0.8% - But Is It A Buy?

Centro de Imagem Diagnósticos S.A.'s (BVMF:AALR3) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Jul 20
Centro de Imagem Diagnósticos S.A.'s (BVMF:AALR3) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Is Centro de Imagem Diagnósticos (BVMF:AALR3) Likely To Turn Things Around?

Jul 03
Is Centro de Imagem Diagnósticos (BVMF:AALR3) Likely To Turn Things Around?

Revenue & Expenses Breakdown

How Alliança Saúde e Participações makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BOVESPA:AALR3 Revenue, expenses and earnings (BRL Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,205-1652870
30 Jun 241,189-2183030
31 Mar 241,171-2703210
31 Dec 231,180-2283250
30 Sep 231,154-2633260
30 Jun 231,132-2873450
31 Mar 231,100-2473400
31 Dec 221,085-2283380
30 Sep 221,092-1353040
30 Jun 221,110-552810
31 Mar 221,127-322800
31 Dec 211,137-62620
30 Sep 211,160382380
30 Jun 211,121292130
31 Mar 21978-661880
31 Dec 20929-971720
30 Sep 20898-1031680
30 Jun 20915-841670
31 Mar 201,047101640
31 Dec 191,073411590
30 Sep 191,069501590
30 Jun 191,073471630
31 Mar 191,076431710
31 Dec 181,077401760
30 Sep 181,074101850
30 Jun 181,08791950
31 Mar 181,08282040
31 Dec 171,07872160
30 Sep 171,081362420
30 Jun 171,042262520
31 Mar 171,015132630
31 Dec 16951152570
30 Sep 16874272380
30 Jun 16806-32230
31 Mar 16734561920
31 Dec 15700-131830
31 Dec 14393-41010
31 Dec 1327628800

Quality Earnings: AALR3 is currently unprofitable.

Growing Profit Margin: AALR3 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AALR3 is unprofitable, and losses have increased over the past 5 years at a rate of 47.4% per year.

Accelerating Growth: Unable to compare AALR3's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AALR3 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (64.3%).


Return on Equity

High ROE: AALR3 has a negative Return on Equity (-13.09%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 07:48
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alliança Saúde e Participações S.A. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pedro MarianiBofA Global Research
Carlos Palhares SequeiraBTG Pactual
Giovana ScottiniEleven Financial Research